Patents Assigned to Eisai R&D Management Co., Ltd.
-
Publication number: 20230148956Abstract: An apparatus for monitoring a user's health and/or sleep and/or the efficacy of a treatment (e.g. a sleep treatment or other type of health treatment) can include use of a wearable electronic device. The device can include an array of sensors for collecting user data. The user data can be used by the device to evaluate criteria related to the user's health to monitor efficacy of a treatment. In addition, or alternatively, the collected data can be transmitted to a central server and/or input/output device for evaluating different criteria for monitoring the user's health and/or sleep as well as the efficacy of a treatment being provided to the user.Type: ApplicationFiled: March 25, 2021Publication date: May 18, 2023Applicant: Eisai R&D Management Co., Ltd.Inventors: Rajeev NARAYANAN, Tushar D. PATEL, Alexander SCOTT, Mitsuo KOSAKA, David LEVIN
-
Publication number: 20230149537Abstract: Provided herein are vaccines including coronavirus antigens and E6020, as well as methods of mitigation of coronavirus infection by administering those vaccines.Type: ApplicationFiled: April 6, 2021Publication date: May 18, 2023Applicants: Eisai R&D Management Co., Ltd., Variation Biotechnologies Inc.Inventors: Fabian GUSOVSKY, Lynn HAWKINS, Sally ISHIZAKA, David Evander ANDERSON, Anne-Catherine FLUCKIGER
-
Patent number: 11643418Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.Type: GrantFiled: March 1, 2021Date of Patent: May 9, 2023Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
-
Patent number: 11642347Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.Type: GrantFiled: March 4, 2020Date of Patent: May 9, 2023Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.Inventors: Heike Keilhack, Sarah K. Knutson, Danielle Johnston Blackwell, Larisa Reyderman, Lone Ottesen
-
Publication number: 20230128195Abstract: The present invention provides methods for the synthesis of ketones involving a Ni/Zr-mediated coupling reaction. The Ni/Zr-mediated ketolization reactions can be used in the synthesis of halichondrins (e.g., halichondrin A, B, C; homohalichondrin A, B, C; norhalichondrin A, B, C), and analogs thereof. Therefore, the present invention also provides synthetic methods useful for the synthesis of halichondrins, and analogs thereof. Also provided herein are compounds (i.e., intermediates) useful in the synthesis of halichondrins, and analogs thereof.Type: ApplicationFiled: November 23, 2022Publication date: April 27, 2023Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Yanran Ai, Ning Ye, Qiaoyi Wang, Kenzo Yahata, Kentaro Iso, Santhosh Reddy Naini, Shuji Yamashita, Jihoon Lee, Isao Ohashi, Takashi Fukuyama
-
Publication number: 20230118596Abstract: Provided herein are methods of treating cancer (e.g., melanoma or RCC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a CTLA4 antagonist; and (c) lenvatinib represented by Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.Type: ApplicationFiled: March 4, 2021Publication date: April 20, 2023Applicants: Merck Sharp & Dohme LLC, EISAI R&D Management Co., Ltd.Inventors: Blanca Homet Moreno, Nageatte Ibrahim, Rodolfo Fleury Perini, Scott J. Diede, Scot W. Ebbinghaus, Rachel Allison Altura
-
Publication number: 20230114089Abstract: The present invention provides a method for producing dopaminergic neuron progenitor cells from pluripotent stem cells, which method comprises the steps of: (i) performing adherent culture of pluripotent stem cells on an extracellular matrix in a medium containing a reagent(s) selected from the group consisting of BMP inhibitor, TGF? inhibitor, SHH signal-stimulating agent, FGF8, and GSK3? inhibitor; (ii) collecting Corin- and/or Lrtm1-positive cells from the cells obtained in Step (i) using a substance which binds to Corin and/or a substance which binds to Lrtm1; and (iii) performing suspension culture of the cells obtained in Step (ii) in a medium containing a neurotrophic factor.Type: ApplicationFiled: May 25, 2022Publication date: April 13, 2023Applicants: KYOTO UNIVERSITY, OSAKA UNIVERSITY, EISAI R&D MANAGEMENT CO., LTD.Inventors: Jun Takahashi, Daisuke Doi, Bumpei Samata, Kiyotoshi Sekiguchi, Yuichi Ono
-
Patent number: 11598776Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.Type: GrantFiled: March 23, 2018Date of Patent: March 7, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
-
Publication number: 20230058779Abstract: Provided herein are methods of treating cancer (e.g., RCC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) lenvatinib represented by Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.Type: ApplicationFiled: December 18, 2020Publication date: February 23, 2023Applicants: Merck Sharp & Dohme LLC, EISAI R&D Management Co., Ltd.Inventors: Rachel A. Altura, Philip E. Brandish, Rodolfo Fleury Perini
-
Patent number: 11578120Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.Type: GrantFiled: September 24, 2020Date of Patent: February 14, 2023Assignees: Eisai R&D Management Co., Ltd., UCL Business LTDInventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
-
Patent number: 11572414Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates such as those comprising eribulin) thereof that bind to mesothelin are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the compositions provided herein.Type: GrantFiled: November 6, 2020Date of Patent: February 7, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Earl F. Albone, Jared Spidel
-
Publication number: 20230026271Abstract: We provide compounds that may be useful as CPS1 inhibitors. These compounds may be useful, for example, in the treatment of cancer.Type: ApplicationFiled: November 20, 2020Publication date: January 26, 2023Applicant: Eisai R&D Management Co., Ltd.Inventors: Alan ROLFE, David BOLDUC, Nicholas LARSEN, Andrew S. COOK, Kiyoyuki OMOTO
-
Publication number: 20230016686Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.Type: ApplicationFiled: June 23, 2022Publication date: January 19, 2023Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer
Patent number: 11547705Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.Type: GrantFiled: March 3, 2016Date of Patent: January 10, 2023Assignees: MERCK SHARP & DOHME LLC, Eisai R&D Management Co., Ltd.Inventors: Andrew Evan Denker, Yu Kato, Kimiyo Tabata, Yusaku Hori -
Patent number: 11548926Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.Type: GrantFiled: March 15, 2017Date of Patent: January 10, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
-
Patent number: 11548898Abstract: The present invention provides methods for the synthesis of ketones involving a Ni/Zr-mediated coupling reaction. The Ni/Zr-mediated ketolization reactions can be used in the synthesis of halichondrins (e.g., halichondrin A, B, C; homohalichondrin A, B, C; norhalichondrin A, B, C), and analogs thereof. Therefore, the present invention also provides synthetic methods useful for the synthesis of halichondrins, and analogs thereof. Also provided herein are compounds (i.e., intermediates) useful in the synthesis of halichondrins, and analogs thereof. In particular, the present invention provides methods and compounds useful in the synthesis of compound of Formula (H3-A).Type: GrantFiled: July 6, 2018Date of Patent: January 10, 2023Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Yanran Ai, Ning Ye, Qiaoyi Wang, Kenzo Yahata, Kentaro Iso, Santhosh Reddy Naini, Shuji Yamashita, Jihoon Lee, Isao Ohashi, Takashi Fukuyama
-
Patent number: 11547743Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 24, 2015Date of Patent: January 10, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Ryo Ohori, Kanta Horie
-
Patent number: 11542269Abstract: The invention provides methods utilizing Prins reaction in the preparation of compounds that may be useful as intermediates in the synthesis of halichondrin macrolides and analogs thereof. The invention also provides compounds that may be useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.Type: GrantFiled: January 3, 2019Date of Patent: January 3, 2023Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Hyeong-Wook Choi, Francis G. Fang
-
Publication number: 20220409724Abstract: The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.Type: ApplicationFiled: October 28, 2020Publication date: December 29, 2022Applicants: Eisai R&D Management Co., Ltd., Merck Sharp & Dohme Corp., MSD International GmbHInventors: Yoichi OZAWA, Yasuhiro FUNAHASHI, Yu KATO
-
Patent number: D980431Type: GrantFiled: March 25, 2021Date of Patent: March 7, 2023Assignee: EISAI R&D MANAGEMENT CO., LTDInventors: Rajeev Narayanan, David Levin, Alexander Scott